

Ralph A H Stewart

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5347265/publications.pdf>

Version: 2024-02-01

95
papers

5,162
citations

81889

39
h-index

91872

69
g-index

97
all docs

97
docs citations

97
times ranked

8345
citing authors

#	ARTICLE	IF	CITATIONS
1	Darapladib for Preventing Ischemic Events in Stable Coronary Heart Disease. <i>New England Journal of Medicine</i> , 2014, 370, 1702-1711.	27.0	467
2	The ABC (age, biomarkers, clinical history) stroke risk score: a biomarker-based risk score for predicting stroke in atrial fibrillation. <i>European Heart Journal</i> , 2016, 37, 1582-1590.	2.2	329
3	Relationship Between Lipid Levels and Clinical Outcomes in the Long-Term Intervention With Pravastatin in Ischemic Disease (LIPID) Trial. <i>Circulation</i> , 2002, 105, 1162-1169.	1.6	244
4	Importance of frailty in patients with cardiovascular disease. <i>European Heart Journal</i> , 2014, 35, 1726-1731.	2.2	239
5	A mobile phone intervention increases physical activity in people with cardiovascular disease: Results from the HEART randomized controlled trial. <i>European Journal of Preventive Cardiology</i> , 2015, 22, 701-709.	1.8	215
6	Text Message and Internet Support for Coronary Heart Disease Self-Management: Results From the Text4Heart Randomized Controlled Trial. <i>Journal of Medical Internet Research</i> , 2015, 17, e237.	4.3	203
7	Effects and costs of real-time cardiac telerehabilitation: randomised controlled non-inferiority trial. <i>Heart</i> , 2019, 105, 122-129.	2.9	192
8	Physical Activity and Mortality in Patients With Stable Coronary Heart Disease. <i>Journal of the American College of Cardiology</i> , 2017, 70, 1689-1700.	2.8	186
9	Accuracy of Cuff-Measured Blood Pressure. <i>Journal of the American College of Cardiology</i> , 2017, 70, 572-586.	2.8	186
10	Inflammatory Biomarkers Interleukin-6 and C-reactive Protein and Outcomes in Stable Coronary Heart Disease: Experiences From the STABILITY (Stabilization of Atherosclerotic Plaque by Initiation of) Trial. <i>Journal of the American College of Cardiology</i> , 2017, 70, 1170-1179.	2.7	170
11	Plasma natriuretic peptide levels increase with symptoms and severity of mitral regurgitation. <i>Journal of the American College of Cardiology</i> , 2003, 41, 2280-2287.	2.8	175
12	Study design and rationale for the clinical outcomes of the STABILITY Trial (Stabilization of) patients with coronary heart disease. <i>American Heart Journal</i> , 2010, 160, 655-661.e2.	2.7	111
13	Dietary patterns and the risk of major adverse cardiovascular events in a global study of high-risk patients with stable coronary heart disease. <i>European Heart Journal</i> , 2016, 37, 1993-2001.	2.2	101
14	Growth Differentiation Factor 15 Predicts All-Cause Morbidity and Mortality in Stable Coronary Heart Disease. <i>Clinical Chemistry</i> , 2017, 63, 325-333.	3.2	97
15	Biomarker-Based Risk Model to Predict Cardiovascular Mortality in Patients With Stable Coronary Disease. <i>Journal of the American College of Cardiology</i> , 2017, 70, 813-826.	2.8	95
16	Cardiovascular Disease and Frailty: What Are the Mechanistic Links?. <i>Clinical Chemistry</i> , 2019, 65, 80-86.	3.2	85
17	Effect of six months' exercise training on C-reactive protein levels in healthy elderly subjects. <i>Journal of the American College of Cardiology</i> , 2004, 44, 2411-2413.	2.8	78
18	Depression and cardiovascular morbidity and mortality: cause or consequence?. <i>European Heart Journal</i> , 2003, 24, 2027-2037.	2.2	72

#	ARTICLE	IF	CITATIONS
19	Left ventricular systolic and diastolic function assessed by tissue Doppler imaging and outcome in asymptomatic aortic stenosis. <i>European Heart Journal</i> , 2010, 31, 2216-2222.	2.2	72
20	Cardiometabolic risk factors in vegans; A meta-analysis of observational studies. <i>PLoS ONE</i> , 2018, 13, e0209086.	2.5	71
21	Plasma proteins associated with cardiovascular death in patients with chronic coronary heart disease: A retrospective study. <i>PLoS Medicine</i> , 2021, 18, e1003513.	8.4	70
22	Effects of exercise training on 5 inflammatory markers associated with cardiovascular risk. <i>American Heart Journal</i> , 2006, 151, 367.e7-367.e16.	2.7	69
23	Physical activity in patients with stable coronary heart disease: an international perspective. <i>European Heart Journal</i> , 2013, 34, 3286-3293.	2.2	67
24	Association of Contemporary Sensitive Troponin I Levels at Baseline and Change at 1 Year With Long-Term Coronary Events Following Myocardial Infarction or Unstable Angina. <i>Journal of the American College of Cardiology</i> , 2014, 63, 345-354.	2.8	61
25	Secondary prevention and risk factor target achievement in a global, high-risk population with established coronary heart disease: baseline results from the STABILITY study. <i>European Journal of Preventive Cardiology</i> , 2013, 20, 678-685.	1.8	60
26	White Blood Cell Count Predicts Reduction in Coronary Heart Disease Mortality With Pravastatin. <i>Circulation</i> , 2005, 111, 1756-1762.	1.6	59
27	Longitudinal left ventricular contractile dysfunction after exercise in aortic stenosis. <i>Heart</i> , 2007, 93, 732-738.	2.9	59
28	Evaluation of a novel sphygmomanometer, which estimates central aortic blood pressure from analysis of brachial artery suprasystolic pressure waves. <i>Journal of Hypertension</i> , 2012, 30, 1743-1750.	0.5	59
29	Increasing Evidence for an Association Between Periodontitis and Cardiovascular Disease. <i>Circulation</i> , 2016, 133, 549-551.	1.6	56
30	Associations between plasma natriuretic peptide levels, symptoms, and left ventricular function in patients with chronic aortic regurgitation. <i>American Journal of Cardiology</i> , 2003, 92, 755-758.	1.6	50
31	Persistent psychological distress and mortality in patients with stable coronary artery disease. <i>Heart</i> , 2017, 103, 1860-1866.	2.9	50
32	Importance of Angina in Patients With Coronary Disease, Heart Failure, and Left Ventricular Systolic Dysfunction. <i>Journal of the American College of Cardiology</i> , 2015, 66, 2092-2100.	2.8	48
33	Improving coronary heart disease self-management using mobile technologies (Text4Heart): a randomised controlled trial protocol. <i>Trials</i> , 2014, 15, 71.	1.6	47
34	Effect of aortic valve replacement on c-reactive protein in nonrheumatic aortic stenosis. <i>American Journal of Cardiology</i> , 2003, 92, 1129-1132.	1.6	45
35	Visit-to-visit variability of blood pressure and cardiovascular outcomes in patients with stable coronary heart disease. Insights from the STABILITY trial. <i>European Heart Journal</i> , 2017, 38, 2813-2822.	2.2	45
36	Lipoprotein-associated Phospholipase A ₂ Activity Is a Marker of Risk But Not a Useful Target for Treatment in Patients With Stable Coronary Heart Disease. <i>Journal of the American Heart Association</i> , 2016, 5, .	3.7	44

#	ARTICLE	IF	CITATIONS
37	Exercise Capacity and Mortality in Patients With Ischemic Left Ventricular Dysfunction Randomized to Coronary Artery Bypass Graft Surgery or Medical Therapy. <i>JACC: Heart Failure</i> , 2014, 2, 335-343.	4.1	43
38	End Users Want Alternative Intervention Delivery Models: Usability and Acceptability of the REMOTE-CR Exercise-Based Cardiac Telerehabilitation Program. <i>Archives of Physical Medicine and Rehabilitation</i> , 2018, 99, 2373-2377.	0.9	43
39	Interleukin 6 and Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Chronic Coronary Syndrome. <i>JAMA Cardiology</i> , 2021, 6, 1440.	6.1	43
40	Biomarkers in stable coronary heart disease, their modulation and cardiovascular risk: The LIPID biomarker study. <i>International Journal of Cardiology</i> , 2015, 201, 499-507.	1.7	42
41	Periodontal disease in patients with chronic coronary heart disease: Prevalence and association with cardiovascular risk factors. <i>European Journal of Preventive Cardiology</i> , 2015, 22, 771-778.	1.8	41
42	A randomized trial of the aldosterone-receptor antagonist eplerenone in asymptomatic moderate-severe aortic stenosis. <i>American Heart Journal</i> , 2008, 156, 348-355.	2.7	37
43	First Identified Case of Fatal Fulminant Necrotizing Eosinophilic Myocarditis Following the Initial Dose of the Pfizer-BioNTech mRNA COVID-19 Vaccine (BNT162b2, Comirnaty): an Extremely Rare Idiosyncratic Hypersensitivity Reaction. <i>Journal of Clinical Immunology</i> , 2022, 42, 441-447.	3.8	36
44	A randomized trial evaluating the effects of change in dairy food consumption on cardio-metabolic risk factors. <i>European Journal of Preventive Cardiology</i> , 2014, 21, 1376-1386.	1.8	35
45	The HEART Mobile Phone Trial: The Partial Mediating Effects of Self-Efficacy on Physical Activity among Cardiac Patients. <i>Frontiers in Public Health</i> , 2014, 2, 56.	2.7	31
46	Changes in high sensitivity troponin T in incident haemodialysis patients. <i>New Zealand Medical Journal</i> , 2016, 129, 23-34.	0.5	31
47	Cardiovascular and Lifestyle Risk Factors and Cognitive Function in Patients With Stable Coronary Heart Disease. <i>Journal of the American Heart Association</i> , 2019, 8, e010641.	3.7	29
48	Pilot Study to Assess the Influence of β -Blockade on Mitral Regurgitant Volume and Left Ventricular Work in Degenerative Mitral Valve Disease. <i>Circulation</i> , 2008, 118, 1041-1046.	1.6	26
49	Thrombosis on a Mechanical Aortic Valve whilst Anti-coagulated With Dabigatran. <i>Heart Lung and Circulation</i> , 2012, 21, 53-55.	0.4	25
50	The Role of Lipoprotein-Associated Phospholipase A2 as a Marker and Potential Therapeutic Target in Atherosclerosis. <i>Current Atherosclerosis Reports</i> , 2011, 13, 132-137.	4.8	22
51	Comparison of four contemporary risk models at predicting mortality after aortic valve replacement. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2015, 149, 443-448.	0.8	22
52	Sex Differences in Clinical Characteristics, Psychosocial Factors, and Outcomes Among Patients With Stable Coronary Heart Disease: Insights from the STABILITY (Stabilization of Atherosclerotic Plaque by) Tj ETQq0 0 0.7gBT /Overlock 10 T	0.7	22
53	Associations between tooth loss and prognostic biomarkers and the risk for cardiovascular events in patients with stable coronary heart disease. <i>International Journal of Cardiology</i> , 2017, 245, 271-276.	1.7	22
54	Living longer by sitting less and moving more. <i>Current Opinion in Cardiology</i> , 2015, 30, 551-557.	1.8	21

#	ARTICLE	IF	CITATIONS
55	Variation in and prognostic importance of troponin T measured using a high-sensitivity assay in clinically stable haemodialysis patients. <i>CKJ: Clinical Kidney Journal</i> , 2013, 6, 402-409.	2.9	20
56	Comparison of Four Risk Scores for Contemporary Isolated Coronary Artery Bypass Grafting. <i>Heart Lung and Circulation</i> , 2014, 23, 469-474.	0.4	20
57	Real-time aortic pulse wave velocity measurement during exercise stress testing. <i>Journal of Cardiovascular Magnetic Resonance</i> , 2015, 17, 86.	3.3	20
58	Changes in Mitral Annular Geometry and Dynamics With β -Blockade in Patients With Degenerative Mitral Valve Disease. <i>Circulation: Cardiovascular Imaging</i> , 2010, 3, 687-693.	2.6	19
59	Body Mass Index and Association With Cardiovascular Outcomes in Patients With Stable Coronary Heart Disease – A STABILITY Substudy. <i>Journal of the American Heart Association</i> , 2022, 11, e023667.	3.7	19
60	Comparison of Risk Scores for Prediction of Complications following Aortic Valve Replacement. <i>Heart Lung and Circulation</i> , 2015, 24, 595-601.	0.4	15
61	Characterization of cardiovascular clinical events and impact of event adjudication on the treatment effect of darapladib versus placebo in patients with stable coronary heart disease: Insights from the STABILITY trial. <i>American Heart Journal</i> , 2019, 208, 65-73.	2.7	14
62	Circulating Cystatin C Is an Independent Risk Marker for Cardiovascular Outcomes, Development of Renal Impairment, and Long-term Mortality in Patients With Stable Coronary Heart Disease: The LIPID Study. <i>Journal of the American Heart Association</i> , 2022, 11, e020745.	3.7	14
63	An Intervention to Improve Medication Adherence in People With Heart Disease (Text4HeartII): Randomized Controlled Trial. <i>JMIR MHealth and UHealth</i> , 2021, 9, e24952.	3.7	13
64	Variation in Blood Levels of Inflammatory Markers Related and Unrelated to Smoking Cessation in Women. <i>Preventive Cardiology</i> , 2007, 10, 68-75.	1.1	12
65	High flow oxygen and risk of mortality in patients with a suspected acute coronary syndrome: pragmatic, cluster randomised, crossover trial. <i>BMJ, The</i> , 2021, 372, n355.	6.0	11
66	Physical activity and mortality in patients with stable coronary heart disease. <i>Current Opinion in Cardiology</i> , 2018, 33, 653-659.	1.8	10
67	Text4Heart II – improving medication adherence in people with heart disease: a study protocol for a randomized controlled trial. <i>Trials</i> , 2018, 19, 70.	1.6	10
68	Self-reported Health and Outcomes in Patients With Stable Coronary Heart Disease. <i>Journal of the American Heart Association</i> , 2017, 6, .	3.7	8
69	The All New Zealand Acute Coronary Syndrome Quality Improvement Programme: Implementation, Methodology and Cohorts (ANZACS-QI 9). <i>New Zealand Medical Journal</i> , 2016, 129, 23-36.	0.5	8
70	Broader indications for B-type natriuretic peptide testing in coronary artery disease. <i>European Heart Journal</i> , 2005, 26, 207-209.	2.2	7
71	Predicting benefit from statins by C-reactive protein, LDL-cholesterol or absolute cardiovascular risk. <i>Future Cardiology</i> , 2009, 5, 231-236.	1.2	7
72	Comparison of effects of losartan and metoprolol on left ventricular and aortic function at rest and during exercise in chronic aortic regurgitation. <i>International Journal of Cardiovascular Imaging</i> , 2018, 34, 615-624.	1.5	7

#	ARTICLE	IF	CITATIONS
73	Risk markers of incident atrial fibrillation in patients with coronary heart disease. <i>American Heart Journal</i> , 2021, 233, 92-101.	2.7	7
74	The Role of Natriuretic Peptides in Patients With Chronic Complex (Mixed or Multiple) Heart Valve Disease. <i>Congestive Heart Failure</i> , 2010, 16, 50-54.	2.0	6
75	Left ventricular thrombus after ST segment elevation myocardial infarction: a single-centre observational study. <i>New Zealand Medical Journal</i> , 2020, 133, 45-54.	0.5	6
76	A simulation of warfarin maintenance dose requirement using a pharmacogenetic algorithm in an ethnically diverse cohort. <i>Personalized Medicine</i> , 2010, 7, 319-325.	1.5	5
77	Medical treatment of asymptomatic chronic aortic regurgitation. <i>Expert Review of Cardiovascular Therapy</i> , 2011, 9, 1249-1254.	1.5	5
78	The learning health system: trial design and participant consent in comparative effectiveness research. <i>European Heart Journal</i> , 2019, 40, 1236-1240.	2.2	5
79	Management of Coronary Disease in Patients with Advanced Kidney Disease. <i>New England Journal of Medicine</i> , 2020, 383, 1090-1092.	27.0	5
80	Meta-Analysis of Bleeding Scores Performance for Acute Coronary Syndrome. <i>Heart Lung and Circulation</i> , 2020, 29, 1749-1757.	0.4	5
81	In patients with stable coronary heart disease, low-density lipoprotein-cholesterol levels ≤ 70 mg/dL and glycosylated hemoglobin A1c $\leq 7\%$ are associated with lower major cardiovascular events. <i>American Heart Journal</i> , 2020, 225, 97-107.	2.7	5
82	Exercise stress echocardiography in patients with valvular heart disease. <i>Journal of Animal Science and Technology</i> , 2015, 2, 89-98.	2.5	4
83	B-type Natriuretic Peptide and Long-term Cardiovascular Mortality in Patients With Coronary Heart Disease. <i>Journal of the American Heart Association</i> , 2022, 11, .	3.7	4
84	Clinical trials in heart valve disease. <i>Current Opinion in Cardiology</i> , 2009, 24, 279-287.	1.8	3
85	The Multi-Ethnic New Zealand Study of Acute Coronary Syndromes (MENZACS): Design and Methodology. <i>Neurology International</i> , 2021, 11, 84-97.	0.5	3
86	Bias in the Evaluation of Effects of Statins on Mortality in Patients with Heart Failure. <i>Heart Lung and Circulation</i> , 2014, 23, 989-990.	0.4	2
87	Longitudinal study of a p21.3 SNP using a national electronic healthcare database. <i>Personalized Medicine</i> , 2010, 7, 361-369.	1.5	1
88	Novel anticoagulants in patients with mechanical heart valves. <i>Evidence-Based Medicine</i> , 2014, 19, 97-97.	0.6	1
89	Contributions of randomized clinical outcome trials to a major cardiology meeting. <i>International Journal of Cardiology</i> , 2016, 222, 931-932.	1.7	1
90	Atrial fibrillation detection in primary care during blood pressure measurements and using a smartphone cardiac monitor. <i>Scientific Reports</i> , 2021, 11, 17721.	3.3	1

#	ARTICLE	IF	CITATIONS
91	Six-minute walk distance after coronary artery bypass grafting compared with medical therapy in ischaemic cardiomyopathy. <i>Open Heart</i> , 2018, 5, e000752.	2.3	1
92	Prehospital identification of ST-segment elevation myocardial infarction and mortality (ANZACS-QI 61). <i>Open Heart</i> , 2022, 9, e001868.	2.3	1
93	Commentary. <i>Evidence-based Cardiovascular Medicine</i> , 2005, 9, 239-240.	0.0	0
94	Natriuretic Peptides in Severe Aortic Stenosis - Role in Predicting Outcomes and Assessment for Early Aortic Valve Replacement. , 2011, , .		0
95	Computers, confounding, clusters, consent, cost, COVID and consultation: how the Health and Disability Code impedes the learning health system. <i>New Zealand Medical Journal</i> , 2020, 133, 138-143.	0.5	0